Welcome to our dedicated page for Precision Optics SEC filings (Ticker: POCI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Precision Optics Corporation, Inc. filings document the regulatory record for a Nasdaq-listed manufacturer of advanced optical instruments and custom optical assemblies. The company’s disclosures identify its common stock, material agreements and capital-structure activity, including underwriting arrangements connected with equity issuance.
Proxy and current-report filings for POCI cover annual meeting votes, director elections, advisory compensation matters, corporate governance, director and executive compensation, beneficial ownership, equity compensation plan information and related-person transaction disclosure. The filing record also provides formal documentation of shareholder voting matters and other material events reported under the Exchange Act.
Precision Optics Corporation, Inc. is conducting a primary offering of 2,777,777 shares of common stock at a public offering price of $3.60 per share via a prospectus supplement dated March 27, 2026. The company expects net proceeds of approximately $9.3 million to be used for working capital and general corporate purposes.
The offering permits the underwriters to purchase an additional 416,667 shares within 45 days. The prospectus lists 7,733,857 shares outstanding as of March 23, 2026 and shows expected common shares outstanding after the offering of 10,511,634 (or 10,928,301 if the option is exercised).
Precision Optics Corporation, Inc. is offering shares of common stock and, at investors' election, pre-funded warrants exercisable for one share at an exercise price of $0.01 per share. The company states its common stock trades on Nasdaq under the symbol POCI and cites a public float market value of $36.3 million computed as of March 25, 2026 based on 7,733,857 shares outstanding as of such date, of which 6,110,561 were held by non-affiliates.
The prospectus supplement describes customary underwriter terms, including a 45-day option to purchase additional shares, lock-up arrangements, and a representative’s warrant equal to 5.0% of shares sold. Net proceeds are expected to be used for working capital and general corporate purposes. The offering disclosure highlights immediate dilution risk, exercise limitations for pre-funded warrants tied to 4.99% or 9.99% beneficial ownership caps, and that the pre-funded warrants will not be listed on any exchange.
Precision Optics Corporation, Inc. held its annual stockholder meeting on March 19, 2026, with 5,950,539 shares voting, representing about 77.07% of the 7,720,229 shares outstanding as of January 29, 2026. Stockholders elected all five director nominees: Peter H. Woodward, Andrew J. Miclot, Buell G. Duncan, Joseph P. Pellegrino, Jr., and Joseph N. Forkey.
Investors also approved, on an advisory basis, the executive compensation program, with 3,009,650 votes for, 4,802 against, and 59,636 abstentions, alongside 2,876,451 broker non-votes. In addition, stockholders ratified the appointment of Stowe & Degon, LLC as independent registered public accounting firm for the fiscal year ending June 30, 2026, with 5,949,026 votes for, 415 against, and 1,098 abstentions.
Precision Optics Corporation director Andrew J. Miclot exercised stock options for 20,000 shares of Common Stock at an exercise price of $1.44 per share on March 12, 2026. To cover tax obligations, 6,372 shares were withheld at $4.52 per share, leaving him with 13,628 shares of Common Stock held directly after the transactions.
Precision Optics Corporation reported sharply higher sales but continued losses for the quarter and six months ended December 31, 2025. Quarterly revenue rose to $7.37 million from $4.53 million, and six-month revenue reached $14.05 million versus $8.72 million, driven mainly by strong Systems Manufacturing growth.
Profitability deteriorated significantly. Gross margin fell to 2.8% for the quarter and 8.2% year-to-date, with gross profit of only $0.20 million in the quarter. The company posted a quarterly net loss of $1.78 million and a six-month net loss of $3.42 million, larger than the prior-year losses.
Liquidity is tight. Cash and cash equivalents were $0.88 million at December 31, 2025, down from $1.77 million at June 30, 2025. Management states existing cash is insufficient to fund planned operations for at least one year from issuance of the statements and concludes there is substantial doubt about the company’s ability to continue as a going concern.
Precision Optics Corporation, Inc. has amended its definitive proxy statement only to update the record date for its 2025 Annual Meeting of Shareholders to January 29, 2026. The annual meeting will be held on March 19, 2026 at the company’s Littleton, MA headquarters.
Shareholders will vote on three key items: electing five directors to one-year terms, approving on an advisory basis executive compensation for the year ended June 30, 2025, and ratifying Stowe & Degon LLC as independent registered public accounting firm for the year ending June 30, 2026. The proxy details board composition, committee structures, director and executive pay (including recent option grants), major shareholders, equity incentive plans, and governance policies such as a clawback policy, insider trading and hedging restrictions, and the process for shareholder proposals for the 2026 meeting.
Precision Optics Corporation, Inc. has scheduled its 2025 Annual Meeting for March 19, 2026 at its Littleton, MA headquarters. Shareholders of record on January 28, 2026 may vote.
Investors will vote on electing five directors, approving on an advisory basis executive compensation, and ratifying Stowe & Degon LLC as independent registered public accounting firm for the year ending June 30, 2026. The Board recommends voting FOR all three proposals.
The proxy outlines a five‑member board with a majority of independent directors and active Audit and Compensation Committees. For fiscal 2025, CEO Joseph N. Forkey received total compensation of $1,106,559, including salary, stock, and options, while total net loss was (5,780,246). The filing also details equity incentive plans and significant holders, including several 5%+ shareholders such as Needham Asset Management and the Pessin family.
Precision Optics Corporation, Inc. (POCI) reported a new equity award to a director on a Form 4. The filing shows a grant of stock options to purchase 30,000 shares of common stock at an exercise price of $4.33 per share on 11/17/2025, reported as an acquisition of derivative securities held directly.
The options expire on 11/17/2035 and were granted under the company’s 2022 Equity Incentive Plan. They vest in four equal installments on December 30, 2025, March 30, 2026, June 29, 2026, and September 29, 2026, conditioned on the director’s continuous service with the company through each applicable vesting date.
Precision Optics Corporation, Inc. (POCI) reported that one of its directors received a grant of 30,000 stock options on 11/17/2025. The options have an exercise price of $4.33 per share and are exercisable for an equal number of shares of common stock, with an expiration date of 11/17/2035. They were granted under the company’s 2022 Equity Incentive Plan.
The options vest in four equal installments on December 30, 2025, March 30, 2026, June 29, 2026, and September 29, 2026, as long as the director remains in continuous employment with Precision Optics through each vesting date. Following this grant, the director holds 30,000 derivative securities directly.
Precision Optics Corporation, Inc. (POCI) reported an insider equity award for a director. The filing shows a grant of stock options, which are rights to buy common stock in the future at a fixed price.
The director received 30,000 stock options with an exercise price of $4.33 per share, becoming exercisable over time. According to the filing, these options vest in four equal installments on December 30, 2025, March 30, 2026, June 29, 2026, and September 29, 2026, as long as the director remains in continuous employment with the company through each vesting date. The options were granted under the company’s 2022 Equity Incentive Plan and are scheduled to expire on November 17, 2035.